Noor Ul Ain Rehman
Thu, May 14, 2026 astatine 11:52 AM CDT 2 min read
Sionna Therapeutics, Inc. (NASDAQ:SION) besides received a standing update from JonesResearch connected April 28. The steadfast lifted the terms people connected the banal to $63 from $52 and maintained a Buy standing connected the shares. The standing update came aft the institution announced the completion of enrollment successful the Phase 2a PreciSION study, with information expected this summer. It told investors successful a probe enactment that the attainment of additive sweat chloride simplification connected SION-719 versus Trikafta unsocial volition found the potency of NBD1 stabilization, portion besides validating the predictive powerfulness of Sionna’s CFHBE assay and boosting assurance successful SION-451 combos.
Sionna Therapeutics, Inc. (NASDAQ:SION) is simply a clinical-stage biopharmaceutical institution progressive successful the research, development, and commercialization of caller medicines for cystic fibrosis.
While we admit the imaginable of SION arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey connected Google News.

2 days ago
3





English (CA) ·
English (US) ·
Spanish (MX) ·